LAGUNA HILLS, Calif., Sept. 30 /PRNewswire/ — Minnow Medical,
Inc., a developer of a novel platform technology employing
radiofrequency thermoplasty for the treatment of in-stent
restenosis and other peripheral vascular conditions, announced
today that veteran medical technology executive Raymond W. Cohen
has been named chief executive officer and a member of the board of
directors.
Cohen, 51, has more than 25 years of leadership and
entrepreneurial experience in health care. For the past four years,
he has been the CEO of CardioPolymers, Inc., a privately-held
developer of novel biotherapeutics for the treatment of congestive
heart failure, which recently merged with LoneStar Heart, Inc.,
where Cohen remains a member of the board of directors. In
2008, during his tenure at CardioPolymers, Inc., Cohen was named by
AeA (now TechAmerica) as the Private Company Life Science CEO of
the Year.
Cohen serves as a member of the board of directors of
publicly-traded Cardiogenesis, Inc., a manufacturer of
transmyocardial revascularization lasers; publicly-traded BioLife
Solutions, Inc., a manufacturer of cryopreservation products used
for human cell and tissue preservation; and Syncroness, Inc., a
privately-held contract engineering and product development firm;
and also serves as an advisor to Fjord Ventures, LLC, a life
science incubator.
Previously, Cohen served as chairman and chief executive officer
of publicly-held Cardiac Science, Inc., a leading U.S. manufacturer
of life-saving automatic public-access defibrillators. In 2004,
Cardiac Science was ranked the 4th fastest growing technology
company in North America on Deloitte & Touche’s Fast 500
listing. During his tenure, Cohen was named Entrepreneur of the
Year in 2002 by the Orange County Business Journal.
Cohen is a member of a number of local Southern California
organizations, notably the Forum of Corporate Directors and OCTANe,
where he is a member of the Biomedical Leaders
‘/>”/>